FirstLook Lung is a blood-based test that helps identify lung cancer risk before or alongside LDCT, for USPSTF-eligible adults. From DELFI Diagnostics. Backed by Menlo.
About the role
Likely people leadership: this role may have 1+ direct report(s) performing transactional P2P/AP work Comfortable operating without a large team — you will be expected to build processes and solutions from the ground up without a team under you
What they're looking for
- 7-10+ years of progressive accounting/finance operations experience, including direct ownership of P2P and ERP systems administration
- Hands-on NetSuite experience required (administrator-level configuration, not just end-user)
- Experience building or scaling accounting, procurement, P2P processes in a growing company (~50-200 employees)
- Strong understanding of internal controls and segregation of duties
- Comfortable operating without a large team — you will be expected to build processes and solutions from the ground up without a team under you
More about this role
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
In our...
Browse similar: Startup jobs · San Francisco Bay Area